Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data

Chandler, David; Szekely, Christine A.; Aggarwal, Shivani; Cyprien, Lori; Bensink, Mark

doi:10.1007/s40122-021-00319-z

Cited by 8 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, this study found that 50 % percent of the patients with standard therapies stopped them within one month, but less than 20 % of the patients on anti-CGRP-mAbs stopped their antibody-therapy within one month [32]. The second study [33] observed a shift to a decreased prescription of preventive medications. The mean time until other ongoing preventive medications were stopped was 185 to 230 days and 36 % had stopped other prophylactics at twelve months, was observed in the third study [35].…”

Section: Prophylactic Medication Apart From Anti-cgrp-mabsmentioning

confidence: 82%

“…An exact breakdown of the search results can be seen in Figure 1. We classified these articles into pharmacoepidemiologic studies (n=8) [32][33][34][35][36][37][38][39], clinicbased studies (n=63) , case reports (n=30) and other articles (n=3) [133][134][135]. Seventy-three articles were retrospective and 31 prospective .…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Five studies assessed the prescription of acute migraine medications six to twelve months before and six to twelve months after first administration of an anti-CGRP-mab. [32,33,35,37,38] The different methods of data representations do not allow to calculate direct comparisons or summaries of data. Comparing baseline to treatment with Erenumab, the prescription of acute migraine medications decreased by 49 % [35] and by 23 % [38], respectively; and the proportion of patients using no prescription acute medication at all or only one type increased [33].…”

Section: Acute Medicationmentioning

confidence: 99%

“…[32,33,35,37,38] The different methods of data representations do not allow to calculate direct comparisons or summaries of data. Comparing baseline to treatment with Erenumab, the prescription of acute migraine medications decreased by 49 % [35] and by 23 % [38], respectively; and the proportion of patients using no prescription acute medication at all or only one type increased [33]. Analyzing specific acute migraine medications, the prescription of non-steroidal anti-inflammatory drugs decreased significantly [37].…”

Section: Acute Medicationmentioning

confidence: 99%

“…Four studies assessed the prescription of prophylactic medications before and after the first administration of an anti-CGRP-mAb. Three studies reported on Erenumab [32,33,35] and one included Erenumab, Fremanezumab and Galcanezumab [39]. In the first, the prescription of other prophylactics decreased by roughly 30 %.…”

Section: Prophylactic Medication Apart From Anti-cgrp-mabsmentioning

confidence: 99%

See 4 more Smart Citations

Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world Data

Pavelic¹,

Wöber²,

Riederer³

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs. Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of Erenumab, Galcanezumab, Fremanezumab, or Eptinezumab in patients with migraine. Results: We identified 104 publications (73 retrospective), comprising 8 pharmaco-epidemiologic and 63 clinic-based studies, 30 case reports and 3 other articles. None of the clinic-based studies provided follow-up data over more than one year in more than 200 patients. Findings suggest reductions in health insurance claims and days with sick-leave as well as better treatment adherence with anti-CGRP-mAbss. Effectiveness, reported in 59 clinic-based studies, was comparable to randomized controlled trials. A treatment pause was associated with an increase in migraine frequency and switching to another antibody resulted in a better response in some of the patients. Adverse events and safety issues were addressed in 70 papers including 22 single case reports. Conclusion: Real-world data on anti-CGRP-mAbs are limited by retrospective data collection, small patient numbers and short follow-up periods. The majority of papers seem to support good effectiveness and tolerability of anti-CGRP-mAbs in the real-world setting. There is an unmet need for large prospective real-world studies providing long-term follow-up of patients treated with anti-CGRP-mAbs.

show abstract

Section: Prophylactic Medication Apart From Anti-cgrp-mabsmentioning

confidence: 82%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Acute Medicationmentioning

confidence: 99%

Section: Acute Medicationmentioning

confidence: 99%

Section: Prophylactic Medication Apart From Anti-cgrp-mabsmentioning

confidence: 99%

See 3 more Smart Citations

Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world Data

Pavelic¹,

Wöber²,

Riederer³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response

Buse,

Krasenbaum,

Seminerio

et al. 2024

Pain Ther

View full text Add to dashboard Cite

Introduction Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide, is indicated for preventive treatment of migraine in adults. Real-world evidence assessing the effect of fremanezumab on migraine-related medication use, health care resource utilization (HCRU), and costs in patient populations with comorbidities, acute medication overuse (AMO), and/or unsatisfactory prior migraine preventive response (UPMPR) is needed. Methods Data for this US, retrospective claims analysis were obtained from the Merative ® MarketScan ® Commercial and supplemental databases. Eligible adults with migraine initiated fremanezumab between 1 September 2018 and 30 June 2019 (date of earliest fremanezumab claim is the index date), had ≥ 12 months of continuous enrollment prior to initiation (preindex period) and ≥ 6 months of data following initiation (postindex period; variable follow-up after 6 months), and had certain preindex migraine comorbidities (depression, anxiety, and cardiovascular disease), potential AMO, or UPMPR. Changes in migraine-related concomitant acute and preventive medication use, HCRU, and costs were assessed pre- versus postindex. Results In total, 3193 patients met the eligibility criteria. From pre- to postindex, mean (SD) per patient per month (PPPM) number of migraine-related acute medication and preventive medication claims (excluding fremanezumab), respectively, decreased from 0.97 (0.90) to 0.86 (0.87) ( P < 0.001) and 0.94 (0.74) to 0.81 (0.75) ( P < 0.001). Migraine-related outpatient and neurologist office visits, emergency department visits, and other outpatient services PPPM decreased pre- versus postindex ( P < 0.001 for all), resulting in a reduction in mean (SD) total health care costs PPPM from US$541 (US$858) to US$490 (US$974) ( P = 0.003). Patients showed high adherence and persistence rates, with mean (SD) proportion of days covered of 0.71 (0.29), medication possession ratio of 0.74 (0.31), and persistence duration of 160.3 (33.2) days 6 months postindex. Conclusions Patients with certain migraine comorbidities, potential AMO, and/or UPMPR in a real-world setting had reduced migraine-related medication use, HCRU, and costs following initiation of fremanezumab. Graphical abstract available for this article. Supplementary Information The online version contains supplementary material available at 10.1007/s40122-024-00583-9.

show abstract

Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 Months Following Initiation of Erenumab: A US Retrospective Real-World Analysis

Urman,

Princic,

Vuvu

et al. 2024

Pain Ther

View full text Add to dashboard Cite

Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data

Cited by 8 publications

References 19 publications

Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world Data

Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world Data

Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response

Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 Months Following Initiation of Erenumab: A US Retrospective Real-World Analysis

Contact Info

Product

Resources

About